What's new? Log in Free sign up

NewAmsterdam Pharma (NAMS)

Company Profile

Company profile

Ticker

NAMS, NAMSW

Exchange

Website

www.newamsterdampharma.com

CEO

Dr. Michael Harvey Davidson FACC, Facp., M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

NewAmsterdam Pharma Co B.V.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NAMS stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

Registration of securities for employees

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Prospectus supplement for primary offering

Registration of additional securities for an S-3

Prospectus supplement for primary offering

Regulation FD Disclosure

Regulation FD Disclosure

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating

Latest ownership filings

View all

Mayur Ian Somaiya

Douglas F Kling

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Mark C. McKenna

der Kamp Hilde Johanna van

Financial summary

Financial statements Chart NAMS financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Nov 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

NAMS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	107	100	+7.0%
Opened positions	23	28	-17.9%
Closed positions	16	8	+100.0%
Increased positions	43	32	+34.4%
Reduced positions	21	17	+23.5%

13F shares	Current	Prev Q	Change
Total value	1.27 tn	1.39 tn	-8.6%
Total shares	109.63 mm	110.76 mm	-1.0%
Total puts	3.60 k	3.20 k	+12.5%
Total calls	65.70 k	75.90 k	-13.4%
Total put/call ratio	0.1	0.0	+30.0%

Largest owners	Shares	Value	Change
Frazier Life Sciences Management	12.86 mm	$213.40 bn	+1.0%
Capital Fund IV Cooperatief U.A. Forbion	11.83 mm	$163.87 mm	0.0%
FCPM Iii Services B.V.	11.83 mm	$196.40 bn	0.0%
Bain Capital Life Sciences Investors	10.47 mm	$173.87 bn	-0.9%
Ra Capital Management	8.06 mm	$133.86 bn	-4.0%
Viking Global Investors	8.02 mm	$133.21 bn	0.0%
Frazier Life Sciences X	7.30 mm	$151.28 mm	0.0%
BCLS II Investco	5.38 mm	$126.99 mm	0.0%
Morningside Venture Investments	4.06 mm	$40.57 mm	0.0%
Frazier Lifesciences Sponsor	3.97 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
AMGN Amgen	0.00	-4.91 mm	EXIT
Millennium Management	16.75 k	-1.15 mm	-98.6%
Siren, L.L.C.	920.56 k	+920.56 k	NEW
Artal	0.00	-800.00 k	EXIT
Woodline Partners	1.16 mm	+681.29 k	+140.9%
JHG Janus Henderson	1.54 mm	+520.77 k	+51.1%
Polar Capital	1.51 mm	+502.41 k	+50.1%
Rock Springs Capital Management	353.32 k	+353.32 k	NEW
Ra Capital Management	8.06 mm	-333.33 k	-4.0%
Pictet Asset Management Holding	1.02 mm	+333.17 k	+48.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NAMS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Jan 25	Douglas F Kling	Ordinary Shares	Sell	Dispose S	No	Yes	0	5,148	0.00	44,000
28 Jan 25	Douglas F Kling	Ordinary Shares	Sell	Dispose S	No	Yes	0	20,237	0.00	49,148
28 Jan 25	Douglas F Kling	Ordinary Shares	Option exercise	Acquire M	No	No	0	25,385	0.00	69,385
28 Jan 25	Douglas F Kling	Option Ordinary Shares	Option exercise	Dispose M	No	No	0	25,385	0.00	296,586
28 Jan 25	Somaiya Mayur Ian	Ordinary Shares	Sell	Dispose S	No	Yes	0	3,405	0.00	38,000
28 Jan 25	Somaiya Mayur Ian	Ordinary Shares	Sell	Dispose S	No	Yes	0	11,495	0.00	41,405
28 Jan 25	Somaiya Mayur Ian	Ordinary Shares	Option exercise	Acquire M	No	No	9.26	14,900	137.97 k	52,900
28 Jan 25	Somaiya Mayur Ian	Option Ordinary Shares	Option exercise	Dispose M	No	No	9.26	14,900	137.97 k	762,814
27 Jan 25	Douglas F Kling	Ordinary Shares	Sell	Dispose S	No	Yes	0	23,815	0.00	44,000
27 Jan 25	Douglas F Kling	Ordinary Shares	Sell	Dispose S	No	Yes	0	80,359	0.00	67,815

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $40 Price Target

RBC Capital analyst Brian Abrahams reiterates NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and maintains $40 price target.

Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)

RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $40 Price Target

RBC Capital analyst Leonid Timashev reiterates NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform and maintains $40 price target.

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma, Maintains $48 Price Target

Press releases

From Benzinga Pro

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini – -- Data

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS, "NewAmsterdam" or the "Company")), a late-stage, clinical biopharmaceutical company developing oral,

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.